1. /
  2. Our work /
  3. Projects /
  4. Burnet Microbiome Initiative: vaginal microbiome in pregnant women in PNG and impact on birth weight and infant growth

Burnet Microbiome Initiative: vaginal microbiome in pregnant women in PNG and impact on birth weight and infant growth

Non-optimal cervicovaginal microbiota are associated with adverse sexual and reproductive health outcomes. However, the nature of the vaginal microbiome in Papua New Guinean women and its role in protecting against or increasing vulnerability to these outcomes are unknown. 

Objective

The role of the vaginal microbiome in protecting against or increasing susceptibility to sexually transmitted infection (STIs) and adverse reproductive health outcomes (such as preterm delivery and low birth weight) is unknown in this cohort of women.

This initiative will advance knowledge of the diversity of vaginal microbiota in women in Papua New Guinea and build our capacity in microbiome research.

Approach

We will analyse samples from Burnet’s Healthy Mothers, Healthy Babies (HMHB) program that aims to identify preventable causes of low birth weight and poor infant growth. 

This study followed 699 women and their infants from pregnancy through to 12 months after birth. Mid-vaginal swabs were collected at the first antenatal visit and post birth as well as extensive demographic, behavioural and clinical data. Eleven percent of babies in this study were low birth weight.  

We will define the composition of maternal vaginal microbiota in pregnancy using next generation sequencing technology and identify classes of vaginal microbiota associated with reduced infant birth weight and growth trajectories.

Community impact

Therapies, such as live biotherapeutics, that aim to alter the microbiota are in pre-clinical development and some have entered clinical trials. Therefore, a detailed knowledge of microbiota features, which pre-dispose mothers to poorer infant growth outcomes, will inform the development of optimal interventions and therapies.

These features may also identify biomarkers that could be used as a prognostic to predict if a woman is at high risk of adverse birth outcomes enabling targeted therapeutic intervention.

Partners

Funding partners

  • Ferring

Collaborators

  • Dr Michelle Scoullar
  • Dr Paul Agius
  • Professor Catriona Bradshaw
  • Professor James Beeson
  • Professor Freya Fowkes
  • Dr Philippe Boeuf

Project contacts

Professor Gilda Tachedjian

Professor Gilda Tachedjian

Head, Life Sciences Discipline; Head, Retroviral Biology and Antivirals Laboratory
View profile
Dr Joshua Hayward

Dr Joshua Hayward

Senior Research Officer
View profile

Project team

Dr Paula Ellenberg

Dr Paula Ellenberg

Laboratory Manager
View profile
Dr Joshua Hayward

Dr Joshua Hayward

Senior Research Officer
View profile
Professor Gilda Tachedjian

Professor Gilda Tachedjian

Head, Life Sciences Discipline; Head, Retroviral Biology and Antivirals Laboratory
View profile
On this page